Methods and Compositions of Direct Reprogramming of Somatic Cells to Stem Cells, and the Use of These Cells

Directly reprogramming stem cells to treat diseases such as Parkinson diseases and other degenerative disorders.

The reprogramming of somatic cells to pluripotent cells, termed induced pluripotent stem (iPS) cells, is well documented. These cells have great therapeutic potential because they can be tailored specifically to a patient or disease. In principle, an individual suffering from a genetic, degenerative, or malignant disorder could submit a biopsy for reprogramming to an iPS cell. Following reprogramming a prescribed course of iPS cell differentiation to a specific tissue type could be initiated that would allow one to cure a given disorder. While experiments have been extremely promising, major hurdles remain to be overcome.

Dr. Yupo Ma, professor in the Department of Pathology at Stony Brook University created an invention which relates generally to direct reprogramming of stem cells, including multipotent or linege-restricted stem cells and their use to treat diseases, such as Parkinson diseases or other degenerative disorders.

Direct reprogramming of amniotic fluid. Feeder free. Allows the removal of episomal vectors from the induced neural system cells without any additional manipulation.

Reprogramming of stem cells to treat diseases such as Parkinson diseases and other degenerative disorders

Utility Patent Filed, Publication No. US2014-0271584

Pre-clinical stage.

Not available for licensing

Exclusive License - All Fields

Stem cells, Neural stem cells, Direct reprogramming, Degenerative disorders 

Patent Information:
Technology/Start-up ID: